Rep. Bruce Westerman Sells GSK plc (NYSE:GSK) Shares

Representative Bruce Westerman (R-Arkansas) recently sold shares of GSK plc NYSE: GSK. In a filing disclosed on May 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in GSK stock on April 21st. The trade occurred in the Representative's "FISHER IRA" account.

Representative Bruce Westerman also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of UniCredit OTCMKTS: UNCRY on 4/21/2025.
• Sold $1,001 - $15,000 in shares of CSX NASDAQ: CSX on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Siemens Aktiengesellschaft OTCMKTS: SIEGY on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Charles Schwab NYSE: SCHW on 4/21/2025.
• Sold $1,001 - $15,000 in shares of The Goldman Sachs Group NYSE: GS on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 4/21/2025.
• Sold $15,001 - $50,000 in shares of NVIDIA NASDAQ: NVDA on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Chevron NYSE: CVX on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Union Pacific NYSE: UNP on 4/21/2025.

GSK Price Performance

Shares of GSK stock traded up $0.07 during trading hours on Friday, hitting $37.64. The company's stock had a trading volume of 7,221,976 shares, compared to its average volume of 4,839,524. The company has a market cap of $77.65 billion, a PE ratio of 23.67, a PEG ratio of 1.12 and a beta of 0.51. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The business has a 50 day moving average price of $37.39 and a two-hundred day moving average price of $35.97. GSK plc has a 12-month low of $31.72 and a 12-month high of $45.80.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. The company had revenue of $10.06 billion for the quarter, compared to analysts' expectations of $7.52 billion. GSK had a return on equity of 48.59% and a net margin of 8.13%. The firm's revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.43 EPS. Analysts expect that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be paid a $0.4216 dividend. This represents a $1.69 dividend on an annualized basis and a yield of 4.48%. The ex-dividend date is Friday, May 16th. This is a positive change from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio is presently 86.60%.

Analysts Set New Price Targets

A number of analysts have issued reports on GSK shares. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 24th. Morgan Stanley began coverage on GSK in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Hsbc Global Res upgraded GSK to a "strong sell" rating in a report on Monday, April 28th. Finally, BNP Paribas assumed coverage on GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price objective on the stock. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $40.58.

Institutional Investors Weigh In On GSK

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Kingsview Wealth Management LLC raised its holdings in GSK by 1.8% during the 1st quarter. Kingsview Wealth Management LLC now owns 15,227 shares of the pharmaceutical company's stock valued at $590,000 after buying an additional 271 shares during the period. Dorsey & Whitney Trust CO LLC raised its stake in shares of GSK by 2.5% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company's stock valued at $389,000 after acquiring an additional 278 shares during the period. Rehmann Capital Advisory Group lifted its holdings in shares of GSK by 4.6% in the 1st quarter. Rehmann Capital Advisory Group now owns 6,407 shares of the pharmaceutical company's stock worth $248,000 after acquiring an additional 279 shares during the last quarter. First PREMIER Bank boosted its stake in shares of GSK by 6.5% during the 1st quarter. First PREMIER Bank now owns 4,659 shares of the pharmaceutical company's stock worth $181,000 after purchasing an additional 286 shares during the period. Finally, Northwest Bank & Trust Co grew its holdings in GSK by 1.3% during the 4th quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company's stock valued at $765,000 after purchasing an additional 289 shares during the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Westerman

Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas' 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027. Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas' 4th Congressional District. He declared candidacy for the 2026 election. Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.